2020
DOI: 10.3389/fsurg.2020.561853
|View full text |Cite
|
Sign up to set email alerts
|

Impact of “Time-From-Biopsy-to-Prostatectomy” on Adverse Oncological Results in Patients With Intermediate and High-Risk Prostate Cancer

Abstract: Objective: Many patients with localized prostate cancer (PCa) do not immediately undergo radical prostatectomy (RP) after biopsy confirmation. The aim of this study was to investigate the influence of "time-from-biopsy-to-prostatectomy" on adverse pathological outcomes. Materials and Methods: Between January 2014 and December 2019, 437 patients with intermediate-and high risk PCa who underwent RP were retrospectively identified within our prospective institutional database. For the aim of our study, we focused… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 26 publications
0
4
0
Order By: Relevance
“…Contrary to this, a delay of 3-6 months was not associated with adverse pathological outcomes for men with intermediate or highrisk prostate cancer. [19][20][21] Ginsburg et al, 22 reviewed delayed prostatectomy (of up to 12 months) in the National Cancer Database and found no early adverse oncological effect. This was the basis of guidelines recommending deferred treatment at the beginning of the pandemic but given we are now living with COVID-19 for over 12 months, we need to consider the impact of ongoing delays.…”
Section: Discussionmentioning
confidence: 99%
“…Contrary to this, a delay of 3-6 months was not associated with adverse pathological outcomes for men with intermediate or highrisk prostate cancer. [19][20][21] Ginsburg et al, 22 reviewed delayed prostatectomy (of up to 12 months) in the National Cancer Database and found no early adverse oncological effect. This was the basis of guidelines recommending deferred treatment at the beginning of the pandemic but given we are now living with COVID-19 for over 12 months, we need to consider the impact of ongoing delays.…”
Section: Discussionmentioning
confidence: 99%
“…Days from biopsy to RP were dichotomized into cut‐offs of ≤90/>90 and ≤180/>180 days to determine the risks of delays associated with PC recurrence using multivariable logistic regression models among the entire cohort and within each quartile of biopsy year. The timeframe cut‐offs were selected a priori as they have previously been shown to have clinical relevance in determining the PC risk of recurrence associated with delays in surgery 23–26 …”
Section: Methodsmentioning
confidence: 99%
“…The timeframe cut-offs were selected a priori as they have previously been shown to have clinical relevance in determining the PC risk of recurrence associated with delays in surgery. [23][24][25][26] In sensitivity analyses, we examined if our results for race and time to RP were modified following the exclusion of men who: (i) may have initially opted for AS and later deciding to have surgery or (ii) were at very low, low or unknown risk using criteria in the NCCN Clinical Practice Guidelines in Oncology given that these men may also have been advised to be on AS. 22 In item (i), owing to a lack of data elements in the SEARCH Cohort to identify men who initially chose AS for primary mode of treatment, we used a 1-year cut-off as a proxy criterion for AS, consistent with our previous work 27 and that of other observational studies.…”
Section: Methodsmentioning
confidence: 99%
“…Defined time limits for treatment decision and initiation could amplify time pressure. However, for low/intermediate risk tumors, an oncological deterioration within three to six months after diagnosis is not very likely [24,25]. Many men may not be aware of this.…”
Section: "[I Have] Decided Too Quickly" (Rp T3)mentioning
confidence: 99%